Medicines Source unknown
Dealstreet

Rajani, Vertices act on La Renon Healthcare investment in Enaltec Labs

The deal values Enaltec at a post-money valuation of ₹180-200 crore.

Bar & Bench

La Renon Healthcare, a pharmaceutical company has acquired 51% stake in Enaltec Labs. The deal values Enaltec at a post-money valuation of ₹180-200 crore.

Rajani Associates advised La Renon Healthcare and the team included:

  • Transation Team - Poorvi Sanjanwala (Partner), Nishtha Mehta (Senior Associate), Kashmira Bakliwal (Senior Associate) and Rutvik Rajagopal (Associate)

  • Diligence Team - Ankur Singhania (Partner), Kashmira Bakliwal, Rohan Gajaria and Rutvik Rajagopal.

Vertices Partners advised Enaltec Labs with a team led by Partners Amit Manubarwala and Vishal Mehta.

Managing Partner, Vinayak Burman provided strategic inputs.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Why Bombay High Court dismissed writ petition by Akasa Air pilot accused of sexual harassment

NCLAT sets aside CCI ban on WhatsApp-Meta data sharing for advertising, upholds ₹213 crore penalty

Delhi High Court quashes defamation case against Arnab Goswami for calling lawyer who attacked Kanhaiya Kumar a goon

Supreme Court seeks Centre's response to plea challenging online gaming law, ban on online real money games

Kerala High Court halts income tax assessment over defective notice format

SCROLL FOR NEXT